SUMMARYThe results of 501 day-case cataract extractions are presented. This is a safe way to manage an operation for which there will be an increased demand. Only 13% of these patients stated that they would have preferred to stay in hospital after surgery.Since our confirmation1 that it is reasonable to do cataract surgery on a day-case basis we have received a number of visits and inquiries about what actually happens in practice. Subsequent cataract patients were carefully monitored, and we report now the results of 292 patients who had operations immediately after the previous series. 276 of these had 501 day-case cataract extractions, and their reactions/response to operation without admission to hospital have been assessed, together with the visual results.The choice of programme for the management of cataract surgery must depend on the results in terms of vision and patient satisfaction, provided of course that those who need operation can have it. We remain convinced that day-case management is preferable to admission to hospital for most patients. Patients and methods PATIENTSTwo hundred and seventy six patients had a total of 501 cataract extractions performed under local anaesthetic as day-cases. Two of these patients went to a convalescent home after operation. Twelve patients (11 under the age of 50 years) required general anaes thesia and were retained in hospital for one night after operation. Two patients had bilateral cataract extraction under local anaesthetic while they were in hospital for medical conditions: (i) arthritis and varicose ulcers; (ii) stabilisation of diabetes. One patient was retained in hospital because bad weather prevented his return home on the day of operation. One patient's retention in hospital was planned, because she was the one who had an expulsive haemorrhage in our previous series. Total: 292 patients.

Dexycu (Icon Bioscience INC, Newark, CA) is an FDAapproved single-dose, sustained release intracameral steroid designed to mitigate postoperative inflammation after cataract surgery as an alternative to topical steroid therapy. The purpose of this study was to look at longterm and adverse events associated with Dexycu use. Eighteen eyes from nine patients who underwent cataract surgery were included. Patients were followed for an average of 97 days (range 28-319 days) after surgery on the first eye. Thirteen eyes were treated with Dexycu, and the other five eyes were treated with standard postoperative anti-inflammatory drops. Four of the thirteen eyes receiving Dexycu developed clinically evident iris atrophy (30.7%). None of the five eyes treated with traditional anti-inflammatory drops developed iris atrophy. The Dexycu intraocular dexamethasone implant was designed to mitigate postoperative inflammation and reduce need for topical therapy but may be associated with other potential adverse effects that warrant consideration.